Aalyria a subpart of Google was founded in 2021. This company builds advanced networking and laser-based communication technology that provides fast, reliable connectivity anywhere on land, sea, air, or in space. Its systems work at any altitude or orbit and support all radio and optical frequencies. The technology helps clients create resilient networks and get more value from their spectrum.

Do read about some of the most popular patents of Aalyria which have been covered by us in this article and also you can find Aalyria patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Aalyria patent portfolio.

How many patents does Aalyria have?

Aalyria has a total of 97 patents globally. These patents belong to 15 unique patent families. Out of 97 patents, 80 patents are active.

How Many Patents did Aalyria File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Aalyria patents are Alive/Dead?

Worldwide Patents

How Many Patents did Aalyria File in Different Countries?

Countries in which Aalyria Filed Patents

Where are Research Centers of Aalyria Patents Located?

The Research Centers of Aalyria Patents the United States of America.

10 Best Aalyria Patents

US11477787B2 is the most popular patent in the Aalyria portfolio. It has received 45 citations so far from company like Digital Global Systems.

Below is the list of 10 most cited patents of Aalyra:

What Percentage of Aalyria US Patent Applications were Granted?

Aalyria (Excluding its subsidiaries) has filed 52 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 39 have been granted leading to a grant rate of 100%.

Below are the key stats of Aalyria patent prosecution at the USPTO.

Which Law Firms are managing US Patents for Aalyria?

What are Aalyria key innovation segments?

What Technologies are Covered by Aalyria?

The chart below distributes patents filed by Aalyria in different countries on the basis of the technology protected in patents. It also represents the markets where Aalyria thinks it’s important to protect particular technological inventions.

R&D Focus: How has Aalyria search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Aalyria?

The post Aalyria Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Kronos Bio was founded in 2017. The company is a clinical-stage biopharmaceutical developer focused on creating innovative cancer therapies. It specializes in discovering and advancing small-molecule drugs that target deregulated transcription an underlying driver of many cancers and autoimmune disorders.

Do read about some of the most popular patents of Kronos Bio which have been covered by us in this article and also you can find Kronos Bio patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Kronos Bio patent portfolio.

How many patents does Kronos Bio have?

Kronos Bio has a total of 196 patents globally. These patents belong to 34 unique patent families. Out of 196 patents, 133 patents are active.

How Many Patents did Kronos Bio File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Kronos Bio patents are Alive/Dead?

Worldwide Patents

How Many Patents did Kronos Bio File in Different Countries?

Countries in which Kronos Bio Filed Patents

Where are Research Centers of Kronos Bio Patents Located?

10 Best Kronos Bio Patents

US8450321B2 is the most popular patent in the Kronos Bio portfolio. It has received 376 citations so far from companies like Gilead Sciences, I-Mab, Phosphorex.

Below is the list of 10 most cited patents of Kronos Bio:

What Percentage of Kronos Bio US Patent Applications were Granted?

Kronos Bio (Excluding its subsidiaries) has filed 57 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 40 have been granted leading to a grant rate of 76.92%.

Below are the key stats of Kronos Bio patent prosecution at the USPTO.

Which Law Firms are managing US Patents for Kronos Bio?

What are Kronos Bio key innovation segments?

What Technologies are Covered by Kronos Bio?

The chart below distributes patents filed by Kronos Bio in different countries on the basis of the technology protected in patents. It also represents the markets where Kronos Bio thinks it’s important to protect particular technological inventions.

R&D Focus: How has Kronos Bio search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Kronos Bio?

The post Kronos Bio Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Helaina was founded in 2019. The company develops milk-equivalent baby formula that serves as an alternative to breast milk. Using fermentation, it produces bioactive proteins to create a new class of functional nutrition products that closely mimic the immune-supporting and nutritional qualities of breast milk, offering infants an option enriched with its immune-nourishing proteins.

Do read about some of the most popular patents of Helaina which have been covered by us in this article and also you can find Helaina patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Helaina patent portfolio.

How many patents does Helaina have?

Helaina has a total of 22 patents globally. These patents belong to 2 unique patent families. Out of 22 patents, 19 patents are active.

How Many Patents did Helaina File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Helaina patents are Alive/Dead?

Worldwide Patents

How Many Patents did Helaina File in Different Countries?

Countries in which Helaina Filed Patents

Where are Research Centers of Helaina Patents Located?

The Research Centers of Helaina Patents is the United States of America.

List of Helaina patents

What are Helaina key innovation segments?

What Technologies are Covered by Helaina?

The chart below distributes patents filed by Helaina in different countries on the basis of the technology protected in patents. It also represents the markets where Helaina thinks it’s important to protect particular technological inventions.

R&D Focus: How has Helaina search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Helaina?

The post Helaina Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Metacrine was founded in 2014. Metacrine is a clinical-stage biopharmaceutical company dedicated to developing differentiated treatments for liver and gastrointestinal disorders. Its work centers on targeting the farnesoid X receptor (FXR), a key regulator of liver and GI disease processes. The company’s FXR-focused pipeline includes the product candidates MET409 and MET642.

Do read about some of the most popular patents of Metacrine which have been covered by us in this article and also you can find Metacrine patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Metacrine patent portfolio.

How many patents does Metacrine have?

Metacrine has a total of 121 patents globally. These patents belong to 22 unique patent families. Out of 121 patents, 30 patents are active.

How Many Patents did Metacrine File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Metacrine patents are Alive/Dead?

Worldwide Patents

How Many Patents did Metacrine File in Different Countries?

Countries in which Metacrine Filed Patents

Where are Research Centers of Metacrine Patents Located?

The Research Centers of Metacrine Patents is the United States of America.

10 Best Metacrine Patents

WO2017049173A1 is the most popular patent in the Metacrine portfolio. It has received 75 citations so far from companies like Bristol-Myers Squibb Company, Enyo Pharma, Tenaya Therapeutics.

Below is the list of 10 most cited patents of Metacrine:

What are Metacrine key innovation segments?

What Technologies are Covered by Metacrine?

The chart below distributes patents filed by Metacrine in different countries on the basis of the technology protected in patents. It also represents the markets where Metacrine thinks it’s important to protect particular technological inventions.

R&D Focus: How has Metacrine search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Metacrine?

The post Metacrine Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Stealth BioTherapeutics was founded in 2007. The company specializes in creating novel therapeutic compounds aimed at treating mitochondrial dysfunction. Its mission centers on the discovery, development, and commercialization of advanced therapies for conditions linked to impaired mitochondrial function and other prevalent age-related diseases.

Do read about some of the most popular patents of Stealth BioTherapeutics which have been covered by us in this article and also you can find Stealth BioTherapeutics patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Stealth BioTherapeutics patent portfolio.

How many patents does Stealth BioTherapeutics have?

Stealth BioTherapeutics has a total of 672 patents globally. These patents belong to 97 unique patent families. Out of 672 patents, 429 patents are active.

How Many Patents did Stealth BioTherapeutics File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Stealth BioTherapeutics patents are Alive/Dead?

Worldwide Patents

How Many Patents did Stealth BioTherapeutics File in Different Countries?

Countries in which Stealth BioTherapeutics Filed Patents

Where are Research Centers of Stealth BioTherapeutics Patents Located?

10 Best Stealth BioTherapeutics Patents

US20130303436A1 is the most popular patent in the Stealth BioTherapeutics portfolio. It has received 64 citations so far from companies like Nacuity Pharmaceuticals, Terenki International Limited.

Below is the list of 10 most cited patents of Stealth BioTherapeutics:

What Percentage of Stealth BioTherapeutics US Patent Applications were Granted?

Stealth BioTherapeutics (Excluding its subsidiaries) has filed 167 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 67 have been granted leading to a grant rate of 47.52%.

Below are the key stats of Stealth BioTherapeutics patent prosecution at the USPTO.

Which Law Firms are managing US Patents for Stealth BioTherapeutics?

What are Stealth BioTherapeutics key innovation segments?

What Technologies are Covered by Stealth BioTherapeutics?

The chart below distributes patents filed by Stealth BioTherapeutics in different countries on the basis of the technology protected in patents. It also represents the markets where Stealth BioTherapeutics thinks it’s important to protect particular technological inventions.

R&D Focus: How has Stealth BioTherapeutics search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Stealth BioTherapeutics?

The post Stealth BioTherapeutics Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Affymax was founded in 2001. Affymax is a development-stage biopharmaceutical company focused on creating novel peptide-based therapies for serious and life-threatening diseases. Its lead product, OMONTYS, is an injectable treatment for anemia associated with chronic kidney disease in adult dialysis patients. OMONTYS is a synthetic, peptide-based erythropoiesis-stimulating agent (ESA) that promotes the production of red blood cells and has been the only ESA in the U.S. approved for once-monthly dosing in this patient population.

Do read about some of the most popular patents of Affymax which have been covered by us in this article and also you can find Affymax patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Affymax patent portfolio.

How many patents does Affymax have?

Affymax has a total of 213 patents globally. These patents belong to 26 unique patent families. Out of 213 patents, 2 patents are active.

How Many Patents did Affymax File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Affymax patents are Alive/Dead?

Worldwide Patents

How Many Patents did Affymax File in Different Countries?

Countries in which Affymax Filed Patents

Where are Research Centers of Affymax Patents Located?

10 Best Affymax Patents

US7084245B2 is the most popular patent in the Affymax portfolio. It has received 323 citations so far from companies like Amgen, Jiangsu Hansoh Pharmaceutical, Intrinsic Lifesciences.

Below is the list of 10 most cited patents of Affymax:

What are Affymax key innovation segments?

What Technologies are Covered by Affymax?

The chart below distributes patents filed by Affymax in different countries on the basis of the technology protected in patents. It also represents the markets where Affymax thinks it’s important to protect particular technological inventions.

R&D Focus: How has Affymax search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Affymax?

The post Affymax Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Zealand Pharma was founded in 2002. Zealand Pharma AS is a biotechnology company that creates and develops peptide-based medicines. Their work focuses on finding new treatments for serious metabolic and gastrointestinal conditions. The company is advancing several promising drug candidates through clinical development. Its research aims to provide better treatment options for patients with unmet medical needs.

The company has also licensed a peptide program to Boehringer Ingelheim, involving a once-weekly dual-acting GLP-1/glucagon agonist currently in early clinical development for obesity and/or Type 2 diabetes.

Do read about some of the most popular patents of Zealand Pharma which have been covered by us in this article and also you can find Zealand Pharma patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Zealand Pharma patent portfolio.

How many patents does Zealand Pharma have?

Zealand Pharma has a total of 1820 patents globally. These patents belong to 163 unique patent families. Out of 1820 patents, 895 patents are active.

How Many Patents did Zealand Pharma File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Zealand Pharma patents are Alive/Dead?

Worldwide Patents

How Many Patents did Zealand Pharma File in Different Countries?

Countries in which Zealand Pharma Filed Patents

Where are Research Centers of Zealand Pharma Patents Located?

10 Best Zealand Pharma Patents

US6939324B2 is the most popular patent in the Zealand Pharma portfolio. It has received 272 citations so far from companies like Medtronic, Valeritas, Allergan.

Below is the list of 10 most cited patents of Zealand Pharma:

What Percentage of Zealand Pharma US Patent Applications were Granted?

Zealand Pharma (Excluding its subsidiaries) has filed 239 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 134 have been granted leading to a grant rate of 70.53%.

Below are the key stats of Zealand Pharma patent prosecution at the USPTO.

Which Law Firms are managing US Patents for Zealand Pharma?

What are Zealand Pharma key innovation segments?

What Technologies are Covered by Zealand Pharma?

The chart below distributes patents filed by Zealand Pharma in different countries on the basis of the technology protected in patents. It also represents the markets where Zealand Pharma thinks it’s important to protect particular technological inventions.

R&D Focus: How has Zealand Pharma search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Zealand Pharma?

The post Zealand Pharma Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Fungible was founded in 2015. Fungible is a technology company that builds powerful chips and systems to make data centers faster and more efficient. Their products help speed up data movement, storage, and security by taking the load off traditional processors. With their advanced hardware and software, Fungible helps companies handle large amounts of data quickly and reliably.

Do read about some of the most popular patents of Fungible which have been covered by us in this article and also you can find Fungible patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Fungible patent portfolio.

How many patents does Fungible have?

Fungible has a total of 52 patents globally. These patents belong to 32 unique patent families. Out of 52 patents, 1 patent is active.

How Many Patents did Fungible File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Fungible patents are Alive/Dead?

Worldwide Patents

How Many Patents did Fungible File in Different Countries?

Countries in which Fungible Filed Patents

Where are Research Centers of Fungible Patents Located?

10 Best Fungible Patents

WO2019014268A1 is the most popular patent in the Fungible portfolio. It has received 26 citations.

Below is the list of 10 most cited patents of Fungible:

List of Fungible patents

What are Fungible key innovation segments?

What Technologies are Covered by Fungible?

The chart below distributes patents filed by Fungible in different countries on the basis of the technology protected in patents. It also represents the markets where Fungible thinks it’s important to protect particular technological inventions.

R&D Focus: How has Fungible search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Fungible?

The post Fungible Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Wastequip was founded in 1989. The company is a manufacturer specializing in waste handling and recycling equipment designed for the industrial sector. The company offers products such as dumpsters, compactors, balers, carts, containers, trailers, and other steel and plastic waste management solutions. These are engineered to collect, process, and transport recyclables, solid waste, liquid waste, and organic materials from residential, commercial, and industrial sources helping clients optimize routes and improve operational efficiency within the waste management industry.

Do read about some of the most popular patents of Wastequip which have been covered by us in this article and also you can find Wastequip patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Wastequip patent portfolio.

How many patents does Wastequip have?

Wastequip has a total of 68 patents globally. These patents belong to 44 unique patent families. Out of 68 patents, 49 patents are active.

How Many Patents did Wastequip File Every Year?

Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.

How many Wastequip patents are Alive/Dead?

Worldwide Patents

How Many Patents did Wastequip File in Different Countries?

Countries in which Wastequip Filed Patents

Where are Research Centers of Wastequip Patents Located?

The Research Centers of Wastequip Patents is the United States of America.

10 Best Wastequip Patents

USD683099S1 is the most popular patent in the Wastequip portfolio. It has received 35 citations so far from companies like Deka Products, Trashbots, Guangdong Bona Robot.

Below is the list of 10 most cited patents of Wastequip:

What are Wastequip key innovation segments?

What Technologies are Covered by Wastequip?

The chart below distributes patents filed by Wastequip in different countries on the basis of the technology protected in patents. It also represents the markets where Wastequip thinks it’s important to protect particular technological inventions.

R&D Focus: How has Wastequip search focus changed over the years?

EXCLUSIVE INSIGHTS COMING SOON!

Interested in knowing about the areas of innovation that are being protected by Wastequip?

The post Wastequip Patents – Insights & Stats (Updated 2025) appeared first on Insights;Gate.

Between October 1 and October 27, a total of 112 reassignment transactions under the United States Patent and Trademark Office (USPTO) encompassed more than 800 unique patents, spanning everything from network & communication (95) and medical & surgical devices (82) to pharmaceuticals (78) semiconductors (30) and recycling/sustainability (23).

This flurry of activity is more than routine housekeeping, it reveals which technologies are emerging as strategic battlegrounds. For example, the wireless‑communications sector is re‑engaging in large‑scale patent movement, underscored by portfolio transactions tied to 4G/5G assets. Meanwhile, the medical‑device industry is seeing a surge of innovation and consolidation in AI‑enabled diagnostics, wearables and surgical robotics.

Why does this matter? Because each transferred patent represents a strategic shift: new ownership, new risk, new opportunity. These aren’t just filings on a ledger; they are levers that influence licensing trajectories, portfolio monetisation, competitive positioning and potential litigation.

As you read on, these transfers will emerge as more than raw data, they are a directional map for where IP value is moving, and where it may be headed next.

Which Technology Areas Are Leading in October 2025 Patent Transfers?

October’s patent transfers offer a clear snapshot of where innovation is surging. The network and communication sector leads the charge with 95 patents moving hands, underscoring the relentless drive towards next-generation networks, from 5G to the early rumblings of 6G. Telecom giants are optimizing their portfolios, divesting older assets and positioning for future advancements in wireless technology.

In parallel, the medical and surgical devices sector saw 82 patents reassigned, reflecting the growing demand for cutting-edge healthcare innovations. From minimally invasive surgeries to wearable health devices, this surge signals the ongoing transformation of the medical landscape, driven by precision technologies and AI-enabled solutions.

Meanwhile, pharmaceuticals and therapeutics saw 78 patents transferred, highlighting the continued investment in drug development, particularly in targeted therapies and biopharmaceuticals. These transfers underscore a vital shift towards personalized medicine and breakthrough treatments aimed at tackling complex health challenges.

Not far behind, design and audio & multimedia technologies also commanded attention, as patents tied to consumer electronics and entertainment media reflected an increasing focus on immersive experiences and advanced product designs.

Additionally, we identified a diverse set of niche technologies spanning textiles, construction, defense and additive manufacturing and others, representing outlier patents that fall outside the broad categories highlighted in the table below.

In sum, these patent transactions reveal much more than simple ownership changes, they point to the emerging technology hubs of tomorrow. For those tracking IP, the story is clear: technology is converging and the next wave of innovation is already taking shape through strategic patent moves.

Who Are the Top Sellers and Buyers Shaping the Patent Landscape in October 2025?

The recent patent assignments in October 2025 offer a fascinating glimpse into the strategic moves across key industries, particularly in medical technology and telecommunications, two sectors experiencing significant consolidation and innovation.

In the medical technology sector, around 23% of all recorded patent transfers were focused on medical and surgical instruments, treatment devices and surgical supplies. Valencell Inc led with the transfer of 44 patents to Vista Primavera Llc, a strategic acquisition likely aimed at expanding Vista’s portfolio in wearable health technologies.

As medical technology continues to advance, the demand for innovative healthcare patents is on the rise. For a more in-depth look at patent activity in the healthcare space, including diagnostic and therapeutic innovations, visit our article on the Healthcare Patent Landscape

Omnia Medical also made headlines by acquiring 23 patents from Orthocision, strengthening its position in the growing field of spinal and orthopedic surgery. These transactions underscore the ongoing consolidation trend in the medical device industry, as companies acquire specialized IP to accelerate innovation and stay competitive in an evolving healthcare landscape, particularly in areas like minimally invasive surgery and sacroiliac joint fusion technologies.

Meanwhile, the telecommunications sector saw major portfolio reshuffling as Ericsson transferred 26 patents to Sago Strategic Solutions Llc, a move that highlights Ericsson’s continued focus on streamlining and monetizing its IP portfolio. Sago, known for acquiring telecom-related patents in 4G, 5G and next-gen technologies such as network slicing and RAN optimization, is positioning itself for continued revenue generation through licensing.

The activity in telecom patents is part of a broader movement towards next-generation networks. If you want to dive deeper into the current 5G patent landscape and understand how these shifts are impacting innovation, check out our comprehensive analysis on the 5G Patent Landscape.

Similarly, Nokia reassigned 21 patents to Piece Future Pte Ltd, reflecting its shift towards an IP-led business model focused on licensing and strategic partnerships. These moves suggest that leading telecom companies are divesting older, non-core assets in favor of refining their portfolios around next-generation technologies like 5G, 6G and cloud-native network solutions.

This dynamic activity among both sellers and buyers illustrates the ongoing shift in IP strategies. Sellers are optimizing their portfolios, divesting older or non-core assets, while buyers are making strategic acquisitions to position themselves for future growth, especially in fast-evolving sectors like telecommunications and healthcare. As these patent transfers unfold, they highlight key opportunities for industry players to capitalize on emerging technologies, monetize existing IP and shape the future of their respective fields.

With over 100 buyers and sellers shaping the landscape, the details of these transactions can offer valuable insights. Interested in accessing the full list? Fill out the form below to get exclusive access to the data.

Which Are the Top 10 Start-ups Involved in the Patent Reassignments in October 2025?

The following table presents the top start-ups that bought or sold patents between October 1 and October 27, 2025, reflecting how young companies are building or streamlining their intellectual property portfolios.

Among emerging companies, a clear bifurcation is visible: start‑ups are either acquiring patents to scale rapidly or selling off assets to monetize early innovation.

Consider the case of Maxeon Solar Pte Ltd, founded in 2020, which bought 11 patents, an aggressive move for a young company in the solar‑tech domain. In contrast, Field Engine Wildlife Research And Management Llc and Alyve Medical Inc sold 4 and 2 patents respectively, suggesting founders are unlocking value early and potentially reinvesting or pivoting.

Notably, several start‑ups that bought patents (e.g., Discord Inc with 4) operate in fast‑moving software or digital ecosystems and appear focused on expanding their IP footprint to strengthen future monetisation or defense.

Meanwhile, sellers are often in more mature niche markets or simply exiting an innovation cycle. This pattern signals a broader trend: start‑ups are no longer just reliant on their own R&D pipeline, they are actively shaping their IP strategy either by buying to build or selling to capitalise.

For stakeholders tracking innovation, these early‑stage moves by start‑ups reveal both where white‑space technology resourcing is happening and where monetisation is already kicking off.

Looking to explore the start-ups actively involved in patent transfers in October? Access the complete list of start-ups by filling out the form below.

Who Are the Top 5 Non-Practicing Entities (NPEs) Involved in Patent Acquisitions?

In October 2025, Non-Practicing Entities (NPEs) continued to play a pivotal role in shaping the patent market. Cogent Insights Licensing Inc stands out with the acquisition of 18 patents, cementing its position as a key player in the IP monetization space.

These acquisitions underscore the growing influence of NPEs in the patent ecosystem, where patents are being acquired not for product development, but to assert rights and generate revenue through licensing or litigation. This offers a critical view into potential litigation risks and opportunities for monetizing unused patents.

Who Are the Top Non-Practicing Entities (NPEs) Involved in Selling Patents?

In October 2025, several Non-Practicing Entities (NPEs) made significant moves in the patent market by selling key assets. Vitaworks IP Llc led the way, parting with 40 patents, reflecting its strategy of capitalizing on its portfolio, likely for monetization or strategic realignment. Similarly, Intellectual Discovery followed with 23 patents sold, positioning itself as a key player in IP transactions.

These patent sales reveal how NPEs are actively engaging in the secondary market, not only acquiring patents for monetization but also selling off portfolios to optimize financial returns or exit certain technology domains.

Such NPE movements provides valuable insight into potential IP acquisition opportunities and emerging trends within specific technology sectors.

To understand the broader implications of how Non-Practicing Entities (NPEs) are shaping patent enforcement strategies, you can explore our detailed article on the NPE Litigation Trend

Curious about the top non-practicing entities (NPEs) shaping patent assignments? Get the full list of NPEs involved in recent transfers by filling out the form below.

How Are Litigation Patterns Shaping Patent Transfers in October 2025?

Out of the 800+ patents reassigned in October 2025, 20 patents have a history of litigation, underscoring the ongoing relevance and high value of these assets. These litigated patents primarily span key technology areas such as telecommunications, cryptography and cybersecurity, speech and audio processing, computer architecture and simulation, and medical instruments and diagnostic devices, sectors where patent strength can significantly influence market positioning and licensing opportunities.

If you’re particularly interested in understanding how US patent litigation cases are shaping the future of patent enforcement, take a closer look at our article on the US Patent Litigation Cases of 2025

A particularly noteworthy transaction involved Kiritin Inc, which transferred three patents to Edgecomm Llc, a known non-practicing entity (NPE) with an active history of IP enforcement. Edgecomm has filed five litigation cases in Texas courts between May and October 2025, suggesting that these newly acquired patents may soon be the subject of further licensing or enforcement actions. This move aligns with Edgecomm’s broader monetization strategy, reinforcing the growing role of NPEs in asserting patents to drive revenue.

In the telecommunications sector, Viewlogic Wireless Llc transferred four patents to Checkwizard Llc, another active NPE known for its aggressive litigation strategy. Checkwizard is currently involved in 11 patent litigation cases against major US banks, including JPMorgan Chase and Bank of America, signaling its intent to use the acquired patents in enforcement actions against high-value sectors like financial services. This move exemplifies the trend where NPEs strategically acquire telecom-related patents to support future litigation or licensing campaigns.

The presence of previously litigated patents in these transactions suggests a more mature IP landscape, where acquisitions are not only about fostering innovation but also about leveraging existing patents that have proven market applicability and legal standing. For patent buyers and NPEs, this is a clear indication that enforcement and licensing strategies are central to how patents are valued and monetized in today’s IP environment.

Want to dive deeper into the patents with litigation history and understand their strategic importance? Reach out to us for more details on these high-value assets.

Navigating the Patent Assignments

October’s patent assignments have shed light on dynamic shifts across industries, with the medical technology sector attracting significant attention. The growing demand for patents in minimally invasive surgery, diagnostic equipment, and wearable health technologies highlights a surge in innovations that integrate sensing, data processing, and therapeutic delivery. These trends open up numerous opportunities for companies holding portfolios in connected healthcare and medical devices.

Simultaneously, telecommunications companies like Ericsson and Nokia are actively streamlining their portfolios, reflecting a shift toward IP monetization and the increasing importance of 5G/6G network solutions. As these technologies continue to evolve, buyers are focusing on acquiring patents that not only enhance their licensing programs but also bolster their positions in next-generation communications.

Moreover, the rising influence of non-practicing entities (NPEs) acquiring patents with prior litigation history underscores the continued focus on enforcement-ready assets. This emphasizes the growing value of patents with proven legal standing and applicability in driving revenue through licensing or litigation.

As the patent landscape evolves, every reassignment marks a strategic shift—whether it’s for innovation, licensing, or monetization. That’s where we come in. We assist clients in maximizing the value of their portfolios through targeted monetization strategies, identifying high-value patents for licensing or sale, preparing litigation-ready claim charts or Licensing Talk Decks, and offering expert advice on portfolio pruning to divest non-core or low-value assets. Let us help you navigate the complexities of the patent market and unlock new opportunities.

The post Technology Transfer October 2025: 800+ Deals Tracked appeared first on Insights;Gate.